Protocol Specific Research

包括分子生物学、基因组学和蛋白质组学在内的许多科学方面的进步已经导致了 在确定癌症的病因和新的治疗方法方面取得了重大进展。需要密切合作 把先进技术从实验室推广到临床这些合作和资源可用于开展 在目前的资助期间，转化临床研究非常富有成效。目前 CCSG为0.25 FTE研究护士和0.5 FTE临床研究专家（CRS）提供资金。的IU 西蒙癌症中心已通过下文详细描述的流程分配了这笔资金，以支持发起 第一阶段和试点研究是非常值得的。ID西蒙癌症中心还提供了 从其他来源获得更多资金，用于进行这些审判。我们预计会有越来越多的病人 由于在本供资期间征聘了 翻译临床研究者（Chiorean、Farag、Hahn和马泰）和计划的I期扩展 在下一个融资周期内。 从2004年到2007年年中，IUSCC通过这一机制支持了15项临床试验。累计患者总数 第132话约会有时，该中心使用额外的资金来支持个别试验。比如说， 另外，国际大学生体育联合会的基金也被用于支持与试验相关的实验室相关研究 由PSR机制支持; PSR资金已用于支持护士和临床研究 专家。在本周期内更新了这一程序，增加了教员人数 进行由检察官发起的试验。PSR支持已优先于将生成 已经（或将）用于支持R21快速试验和其他同行评审资金的初步数据 应用. 2006年更新了为开展试点临床试验寻求资金的程序，并向所有人开放 IUCC成员通过http://cancer.iu.edu/research/fundinq/clin trial.php上的连续RFA找到。的 公告详细说明了一个事实，即协议特定的研究资金涵盖了一个核心小组的费用， 研究护士和数据管理员（临床研究专家）进行高优先级，创新， 可行性或原理性临床试验。这些资金申请将用于对一个项目进行早期测试， 用于预防或治疗癌症的候选药剂或装置。收到并审查申请 每月由临床研究委员会。

Advances in many aspects of science including molecular biology, genomics and proteomics have resulted in significant advances in defining the causes of and new treatments for cancer. Close collaborations are needed to take advances from the laboratory into the clinic. These collaborations and resources available to conduct translational clinical research have been very productive during the current funding period. Currently, the CCSG provides funding for 0.25 FTE research nurse and 0.5 FTE clinical research specialist (CRS). The IU Simon Cancer Center has allocated this money by a process described in detail below to support investigatorinitiated Phase I and pilot studies that are highly meritorious. The ID Simon Cancer Center also provided additional funds from other sources for the conduct of these trials. We anticipate growing numbers of patients accrued to future phase I and pilot studies because of the recruitment during the current funding period of translational clinical investigators (Chiorean, Farag, Hahn, and Matei) and planned expansion of our phase I program during the next funding period. From 2004 through mid-2007, the IUSCC supported 15 clinical trials by this mechanism. Total patient accrual is to date 132. On occasion, the Center used additional funds to support individual trials. For example, additional IUSCC funds have been used to support the laboratory correlative studies associated with a trial supported by the PSR mechanism; the PSR funding has been used to support nurses and clinical research specialists. The process has been updated during the current cycle with resulting increased number of faculty conducting investigator-initiated trials. PSR support has been prioritized to protocols that will generate preliminary data that has been (or will be) used to support R21 Quick Trials and other peer-reviewed funding applications. The process to seek funding for the conduct of pilot clinical trials was updated in 2006 and is available to all IUCC members via a continuous RFA found at http://cancer.iu.edu/research/fundinq/clin trial.php. The announcement details the fact that Protocol Specific Research funding covers the cost of a core group of research nurses and data managers (clinical research specialists) for the conduct of high priority, innovative, feasibility or proof-of-principle clinical trials. The requests for funding are to be used for early-phase testing of a candidate agent or device for the prevention or treatment of cancer. Applications are received and reviewed monthly by the Clinical Research Committee.